Featuring 60 Cell & Gene Therapy companies from China, Taiwan, Korea, Japan, South Asia, SEA, and Australia! APAC Cell & Gene Therapy Market 2021 covers comprehensive information on parameters such as product pipeline, future expansion plans, technologies used, production capacity, temperature requirements, manufacturing capabilities, and SCM preferences. It also contains analysis on market growth, M&As, financial updates, upcoming facilities and more. It provides readers a closer look into companies such as Chugai, Tessa Therapeutics, Daewong Pharm, Eutilex, Carmine Therapeutics, Sumitomo Dainippon, Unicocell Biomed, JW Creagene, Takara Bio and more.
APAC Cell & Gene Therapy Market
$5,998 – $9,998
KEY TAKEAWAYS
- Insights on production processes, equipment, logistics and SCM services various BioPharmas and CMOs currently and plan to employ.
- Understand the facility expansion plans of key players in the APAC region.
- Identify potential clients who would be interested in your latest technology or service.
KEY TAKEAWAYS
- Insights on production processes, equipment, logistics and SCM services various BioPharmas and CMOs currently and plan to employ.
- Understand the facility expansion plans of key players in the APAC region.
- Identify potential clients who would be interested in your latest technology or service.
product details
- 1Table of Contents
- 2Companies Mentioned
- 3User Access
Section 1
- Preface
- Report Scope & Data Coverage
- IMAPAC’s Research Methodology
Section 2 – Company-Wise Analysis
- Company Overview
- GMP Certifications
- Facilities’ Size, Equipment, Capabilities etc.
- Expansion Plans
- Current Product Pipeline
- Stage of Development
- Production Capacity
- Platform Technologies
- Product Temperature Requirements
- Preferred Delivery and SCM methods
- Partnerships & Collaborations
- Financial Performance
- Company Highlights, News & Updates
- Interviews
Section 3: Region-Wise Data & Analysis
- Distribution of Cell & Gene Therapy Companies
- Targeted Disease Types
- Stage of clinical trial phase
- Allogenic vs Autologous Therapies
- Targeted Antigens
Section 4
- Bibiliography
- Disclaimer
- About Us
- Our Other Reports
Facilities: Greater China
- Henlius Pharma
- Innovent Biologics
- Pfizer
- Tonhua Dongbao
- AlphaMab
- Akeso Pharmaceuticals
- Hanmi Pharma
- Sinovac
- BeiGene
- Junshi Biosciences
- Tot Biopharma
- Hualan Biological Engineering
Facilities: Korea and Japan
- Samsung Bioepis
- Astellas
- Celltrion
- Chugai
- Hanmi Pharma
- Kyowa Hakko Kirin
- Aprogen Biologiccs
- Daiichi Sankyo
Facilities: India and Australia
- Aurobindo
- CSL Bering
- Serum Institute of India
- CSIRO
- Enzene Biosciences
- Stelis Biopharma
Facilities: Southeast Asia
- Abbvie
- GSK
- AJ Biologics
- Amgen
- Novartis Thailand
- Baxter
- Takeda
- Siam Biosciences
Single - User Access
This license grants the right of use of the purchased report to a single recipient only. You may access the material on your computer, as and when required, for your own personal use.
Multi - User Access
Upto 3 users: This license grants the right of use of the purchased report by upto 3 users of the same firm/enterprise.
Corporate Access
Unlimited user access (Within your organization): This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the number of users.
Get In Touch
